Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

OBJECTIVES: The randomized Phase IIIb/IV EXTEND trial showed that extended-pulsed fidaxomicin significantly improved sustained clinical cure and reduced recurrence versus vancomycin in patients ≥60 years old with Clostridium difficile infection (CDI). Cost-effectiveness of extended-pulsed fidaxomici...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Antimicrob Chemother
Main Authors: Cornely, Oliver A, Watt, Maureen, McCrea, Charles, Goldenberg, Simon D, De Nigris, Enrico
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105871/
https://ncbi.nlm.nih.gov/pubmed/29800295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky184
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares